$5.10−0.12 (−2.30%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
BioAge Labs (BIOA) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
12 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue history is too short to read a growth trend, net margin −896.1%.
The four lines that matter · FY23–FY25
Revenue ($M)—
9.0
FY23→FY25CAGR —
Net income ($M)▼13.4%
−80.6
FY23→FY25CAGR —
Free cash flow ($M)▼58.7%
−82.3
FY23→FY25CAGR —
Diluted EPS▲66.2%
−2.24
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)
-896¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Operating Net
Net margin -896.1% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.
The receipt · income statement · FY23–FY25 USD millions except per-share & ratios · hover a line for its definition
The annual and quarterly statements are struck on share counts that differ by a factor of 0.7827, so per-share figures cannot be compared across the two tables. Each table's per-share figures are on its own share basis.
USD millions except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | YoY | CAGR 23→25 |
|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||
Revenue | 8.6 | 9.0 | 0.0 | 0.0 | — | — |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | 0.0 | 0.0 | — | — |
Research & development | 99.5 | 74.0 | 59.0 | 33.9 | ▲25.3% | +47.7% |
Selling, general & admin | 29.6 | 27.8 | 19.2 | 14.5 | ▲45.2% | +38.4% |
Total operating expenses | 129.1 | 101.8 | 78.2 | 48.4 | ▲30.2% | +45.0% |
Operating incomefeeds ROC rank | −120.5 | −92.8 | −78.2 | −48.4 | ▼18.7% | — |
Other income, net | 13.3 | 12.4 | 7.0 | −15.5 | — | — |
Pretax income | −107.3 | −80.4 | −71.2 | −63.9 | ▼12.9% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −107.8 | −80.6 | −71.1 | −63.9 | ▼13.4% | — |
| Per share | ||||||
Diluted EPSbuyback-sensitive | −2.55 | −2.24 | −6.63 | −38.17 | ▲66.2% | — |
Diluted shares (mn) | 45.91 | 35.93 | 10.73 | 1.67 | ▲235.0% | +363.5% |
| Margins | ||||||
Gross margin | —A | —A | — | — | — | — |
Operating margin | −1401.8% | −1031.5% | — | — | — | — |
Net margin | −1253.6% | −896.1% | — | — | — | — |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was BioAge Labs' net income?
BioAge Labs reported net income of −$80.6M in fiscal 2025, a net margin of −896.1%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

